Thorleif Møller
Thorleif is the inventor of the Blockmir technology upon which Mirrx Therapeutics is founded. Thorleif holds a Ph.D in molecular biology and has worked extensively with RNA-based gene regulation in bacteria. Among others, he discovered that a protein co-factor, Hfq, facilitate RNA:RNA interactions, and is key to RNA-based gene regulation in bacteria. Mirrx Therapeutics is the second venture-backed company founded by Thorleif. Thorleif has worked as an IP-consultant for more than 5 years and thus has major experience with protecting new technologies and devising IP-strategies.
